2023 was a tough calendar year with the biopharma field, with quite a few corporations downsizing and restructuring their workforces to stay afloat. You can find indications of recovery, as mergers and acquisitions picked up through the pharmaceutical and existence sciences industry while in the latter A part of 2023 https://sites.google.com/view/bio-sites/blog